{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:08:38Z","timestamp":1791328118371,"version":"4.3.1"},"reference-count":72,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.1210\/en.2016-1903","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T15:25:49Z","timestamp":1492615549000},"page":"1595-1611","source":"Crossref","is-referenced-by-count":26,"title":["Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy"],"prefix":"10.1210","volume":"158","author":[{"given":"Keshuo","family":"Ding","sequence":"first","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Department of Pathology, Anhui Medical University, Hefei, Anhui 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yun","family":"Chong","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore 117599"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Yang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Li","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Kong","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxu","family":"Qian","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Xiong","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Pandey","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore 117599"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Ma","sequence":"additional","affiliation":[{"name":"Tsinghua-Berkeley Shenzhen Institute and Division of Life Sciences and Health, Tsinghua University Graduate School, Shenzhen 518055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anhui Medical University, Hefei, Anhui 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Lobie","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore 117599"},{"name":"Tsinghua-Berkeley Shenzhen Institute and Division of Life Sciences and Health, Tsinghua University Graduate School, Shenzhen 518055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2019041121300784200_B1","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.ijgo.2015.06.010","article-title":"Pathology of cancers of the female genital tract","volume":"131","author":"Prat","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"issue":"8","key":"2019041121300784200_B2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ejso.2006.03.046","article-title":"Management of endometrial cancer","volume":"32","author":"Kitchener","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2019041121300784200_B3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.seminoncol.2008.12.006","article-title":"Management of advanced-stage and recurrent endometrial cancer","volume":"36","author":"Ray","year":"2009","journal-title":"Semin Oncol"},{"issue":"4","key":"2019041121300784200_B4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1593\/tlo.09325","article-title":"Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24","volume":"3","author":"Pandey","year":"2010","journal-title":"Transl Oncol"},{"issue":"12","key":"2019041121300784200_B5","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-08-4652","article-title":"Biological significance of prolactin in gynecologic cancers","volume":"69","author":"Levina","year":"2009","journal-title":"Cancer Res"},{"key":"2019041121300784200_B6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.physiol.64.081501.131049","article-title":"Prolactin: the new biology of an old hormone","volume":"64","author":"Goffin","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"2019041121300784200_B7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/BD-2003-18108","article-title":"Role of prolactin\/prolactin receptor signaling in human breast cancer","volume":"18","author":"Clevenger","year":"2003","journal-title":"Breast Dis"},{"issue":"7","key":"2019041121300784200_B8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2826.2010.02011.x","article-title":"Prolactin and human tumourogenesis","volume":"22","author":"Fernandez","year":"2010","journal-title":"J Neuroendocrinol"},{"issue":"20","key":"2019041121300784200_B9","doi-asserted-by":"crossref","first-page":"29465","DOI":"10.18632\/oncotarget.8781","article-title":"Human growth hormone and human prolactin function as autocrine\/paracrine promoters of progression of hepatocellular carcinoma","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"issue":"21","key":"2019041121300784200_B10","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019041121300784200_B11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.1191","article-title":"Plasma prolactin and prostate cancer risk: a prospective study","volume":"92","author":"Stattin","year":"2001","journal-title":"Int J Cancer"},{"issue":"10","key":"2019041121300784200_B12","doi-asserted-by":"crossref","first-page":"E1619","DOI":"10.1210\/jc.2011-1245","article-title":"Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma","volume":"96","author":"Wu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041121300784200_B13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2007.05.041","article-title":"Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin","volume":"107","author":"Yurkovetsky","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2019041121300784200_B14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1043-2760(02)00603-3","article-title":"Prolactin as an autocrine\/paracrine growth factor in human cancer","volume":"13","author":"Ben-Jonathan","year":"2002","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2019041121300784200_B15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/eem.11.19","article-title":"Lactogens and estrogens in breast cancer chemoresistance","volume":"6","author":"Idelman","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2019041121300784200_B16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tem.2010.08.004","article-title":"Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor","volume":"21","author":"Jacobson","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2019041121300784200_B17","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1677\/ERC-09-0253","article-title":"Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy","volume":"17","author":"LaPensee","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2019041121300784200_B18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/carcin\/bgp120","article-title":"Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase","volume":"30","author":"LaPensee","year":"2009","journal-title":"Carcinogenesis"},{"key":"2019041121300784200_B19","first-page":"1131","article-title":"A clinical study of Taxotere versus Taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines","volume":"22","author":"Lissoni","year":"2002","journal-title":"Anticancer Res"},{"issue":"2","key":"2019041121300784200_B20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/cmi.2009.119","article-title":"CD24: from A to Z","volume":"7","author":"Fang","year":"2010","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2019041121300784200_B21","first-page":"309","article-title":"Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium","volume":"24","author":"Kim","year":"2009","journal-title":"Histol Histopathol"},{"issue":"3","key":"2019041121300784200_B22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/B:HIJO.0000032357.16261.c5","article-title":"Tumour biological aspects of CD24, a mucin-like adhesion molecule","volume":"35","author":"Kristiansen","year":"2004","journal-title":"J Mol Histol"},{"issue":"23","key":"2019041121300784200_B23","doi-asserted-by":"crossref","first-page":"10783","DOI":"10.1158\/0008-5472.CAN-05-0619","article-title":"CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis","volume":"65","author":"Baumann","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"2019041121300784200_B24","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/0008-5472.CAN-05-3855","article-title":"The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer","volume":"66","author":"Smith","year":"2006","journal-title":"Cancer Res"},{"issue":"13","key":"2019041121300784200_B25","first-page":"4906","article-title":"CD24 expression is a new prognostic marker in breast cancer","volume":"9","author":"Kristiansen","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019041121300784200_B26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","article-title":"CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival","volume":"161","author":"Kristiansen","year":"2002","journal-title":"Am J Pathol"},{"issue":"2","key":"2019041121300784200_B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2012.09.067","article-title":"Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells","volume":"427","author":"Koh","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"1-2","key":"2019041121300784200_B28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2004.04.001","article-title":"Prolactin-modulated gene expression profiles in pancreatic islets from adult female rats","volume":"220","author":"Bordin","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2019041121300784200_B29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/107327480901600106","article-title":"Current treatment of metastatic endometrial cancer","volume":"16","author":"Temkin","year":"2009","journal-title":"Cancer Control"},{"issue":"8","key":"2019041121300784200_B30","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1210\/en.2008-0286","article-title":"Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells","volume":"149","author":"Pandey","year":"2008","journal-title":"Endocrinology"},{"issue":"19","key":"2019041121300784200_B31","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/onc.2009.66","article-title":"Artemin is oncogenic for human mammary carcinoma cells","volume":"28","author":"Kang","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"2019041121300784200_B32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/en.2009-0651","article-title":"Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior","volume":"151","author":"Tang","year":"2010","journal-title":"Endocrinology"},{"issue":"5381","key":"2019041121300784200_B33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.281.5381.1317","article-title":"A matter of life and cell death","volume":"281","author":"Evan","year":"1998","journal-title":"Science"},{"issue":"1","key":"2019041121300784200_B34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"4","key":"2019041121300784200_B35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/adt.2014.573","article-title":"Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors","volume":"12","author":"Edmondson","year":"2014","journal-title":"Assay Drug Dev Technol"},{"issue":"1","key":"2019041121300784200_B36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jcp.2006.043794","article-title":"Progressive derailment of cell cycle regulators in endometrial carcinogenesis","volume":"61","author":"Horr\u00e9e","year":"2008","journal-title":"J Clin Pathol"},{"issue":"5","key":"2019041121300784200_B37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/0008-5472.CAN-07-5983","article-title":"CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability","volume":"68","author":"Ray","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"2019041121300784200_B38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-29-14","article-title":"Relevance of Bcl-x expression in different types of endometrial tissues","volume":"29","author":"Ma","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2019041121300784200_B39","first-page":"3977","article-title":"BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry","volume":"29","author":"Porichi","year":"2009","journal-title":"Anticancer Res"},{"issue":"3","key":"2019041121300784200_B40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1210\/en.2009-0979","article-title":"Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells","volume":"151","author":"Pandey","year":"2010","journal-title":"Endocrinology"},{"issue":"7","key":"2019041121300784200_B41","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"2019041121300784200_B42","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1101\/gad.1395006","article-title":"The deficiency of Akt1 is sufficient to suppress tumor development in Pten+\/- mice","volume":"20","author":"Chen","year":"2006","journal-title":"Genes Dev"},{"issue":"2-3","key":"2019041121300784200_B43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jsbmb.2003.08.004","article-title":"Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth","volume":"87","author":"Dai","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2019041121300784200_B44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/IGC.0b013e318216a169","article-title":"KCC1 gene advances cell invasion ability by regulating ERK signaling pathway in endometrial cancer HEC-1B cell line","volume":"21","author":"Shang","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"2019041121300784200_B45","first-page":"500","article-title":"CD24 expression is a poor prognostic marker in endometrial carcinoma","volume":"27","author":"Karahan","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"2019041121300784200_B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/WHE.13.4","article-title":"Targeted endometrial cancer therapy as a future prospect","volume":"9","author":"Thanapprapasr","year":"2013","journal-title":"Womens Health (Lond)"},{"issue":"5","key":"2019041121300784200_B47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3892\/mco.2013.140","article-title":"Current status of molecular-targeted drugs for endometrial cancer","volume":"1","author":"Nogami","year":"2013","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"2019041121300784200_B48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2011.06.014","article-title":"Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists","volume":"310","author":"Tan","year":"2011","journal-title":"Cancer Lett"},{"issue":"6","key":"2019041121300784200_B49","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3892\/ijo.2012.1660","article-title":"The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells","volume":"41","author":"Hou","year":"2012","journal-title":"Int J Oncol"},{"key":"2019041121300784200_B50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fendo.2015.00186","article-title":"Prolactin promotes breast cancer cell migration through actin cytoskeleton remodeling","volume":"6","author":"da Silva","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2019041121300784200_B51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-12114-7_5","article-title":"Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion","volume":"846","author":"Hammer","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"2019041121300784200_B52","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/me.2012-1322","article-title":"PAK1 regulates breast cancer cell invasion through secretion of matrix metalloproteinases in response to prolactin and three-dimensional collagen IV","volume":"27","author":"Rider","year":"2013","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2019041121300784200_B53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/me.2015-1299","article-title":"Prolactin signaling stimulates invasion via Na(+)\/H(+) exchanger NHE1 in T47D human breast cancer cells","volume":"30","author":"Pedraz-Cuesta","year":"2016","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2019041121300784200_B54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1677\/ERC-06-0050","article-title":"Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration","volume":"14","author":"D\u00f6ll","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041121300784200_B55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2015.06.010","article-title":"Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer","volume":"366","author":"Yonezawa","year":"2015","journal-title":"Cancer Lett"},{"issue":"2","key":"2019041121300784200_B56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjc.6601947","article-title":"Prolactin acts as a potent survival factor for human breast cancer cell lines","volume":"91","author":"Perks","year":"2004","journal-title":"Br J Cancer"},{"key":"2019041121300784200_B57","doi-asserted-by":"crossref","first-page":"25998","DOI":"10.1038\/srep25998","article-title":"Plasma prolactin and breast cancer risk: a meta-analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"2019041121300784200_B58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1053\/ejso.2000.0943","article-title":"Prolactin as a local growth promoter in patients with breast cancer: GCRI experience","volume":"26","author":"Bhatavdekar","year":"2000","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2019041121300784200_B59","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","article-title":"Bcl2 family proteins in carcinogenesis and the treatment of cancer","volume":"14","author":"Frenzel","year":"2009","journal-title":"Apoptosis"},{"issue":"33","key":"2019041121300784200_B60","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/sj.onc.1205637","article-title":"Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R","volume":"21","author":"Beck","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"2019041121300784200_B61","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.onc.1207245","article-title":"Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice","volume":"23","author":"Peirce","year":"2004","journal-title":"Oncogene"},{"issue":"4","key":"2019041121300784200_B62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ijc.20810","article-title":"Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment","volume":"115","author":"Asai-Sato","year":"2005","journal-title":"Int J Cancer"},{"issue":"4","key":"2019041121300784200_B63","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2129","article-title":"Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity","volume":"10","author":"Howell","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2019041121300784200_B64","first-page":"25","article-title":"In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells","volume":"18","author":"Ramamoorthy","year":"2001","journal-title":"Int J Oncol"},{"issue":"1","key":"2019041121300784200_B65","first-page":"27","article-title":"Efficacy of monochemotherapy with docetaxel (Taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer","volume":"22","author":"Lissoni","year":"2001","journal-title":"Neuroendocrinol Lett"},{"issue":"10","key":"2019041121300784200_B66","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1158\/1535-7163.MCT-15-0187","article-title":"Met signaling cascade is amplified by the recruitment of phosphorylated met to lipid rafts via CD24 and leads to drug resistance in endometrial cancer cell lines","volume":"14","author":"Ono","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2019041121300784200_B67","first-page":"165","article-title":"Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients","volume":"57","author":"Horiguchi","year":"2010","journal-title":"J Med Dent Sci"},{"issue":"1","key":"2019041121300784200_B68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10735-013-9523-6","article-title":"CD44\/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy","volume":"45","author":"Adamczyk","year":"2014","journal-title":"J Mol Histol"},{"issue":"1","key":"2019041121300784200_B69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.stem.2011.06.005","article-title":"CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation","volume":"9","author":"Lee","year":"2011","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2019041121300784200_B70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ncpendmet0270","article-title":"Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"7","key":"2019041121300784200_B71","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-12-0138","article-title":"Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer","volume":"19","author":"Damiano","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019041121300784200_B72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1634\/theoncologist.2016-0108","article-title":"Targeting prolactin receptor (PRLR) signaling in PRLR-positive breast and prostate cancer","volume":"21","author":"O\u2019Sullivan","year":"2016","journal-title":"Oncologist"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/158\/6\/1595\/17643367\/en.2016-1903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T17:25:50Z","timestamp":1719163550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/158\/6\/1595\/2997446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2016-1903","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,1]]},"published":{"date-parts":[[2017,2,15]]}}}